Medtronic has entered a new outcomes-based agreement with US healthcare firm Aetna to investigate health outcomes in diabetes patients switching to pump therapy using its insulin pump that employs SmartGuard Technology and the new MiniMed 670G system.
The solution is designed to self-adjust to maintain patients blood sugar levels according to their personal requirements.
The study will include type 1 and type 2 diabetes patients who are currently on several daily insulin injections for diabetes management.
